Impact of hospitalizations for bronchiolitis in preterm infants on long-term health care costs in Italy: a retrospective case-control study.
Roggeri DP, Roggeri A, Rossi E, Cataudella S, Martini N. Clinicoecon Outcomes Res. 2016 Aug 4;8:407-12. doi: HTTP://DX.DOI.ORG/10.2147/CEOR.S111535. eCollection 2016.
End-stage Renal Disease Costs for Patients New to Hemodialysis in Italy: The FARO-2 Study.
Roggeri DP, Roggeri A, Brancaccio D, Mazzaferro S, Messa P, Paoletti E, Possidoni A, Costanzo AM, di Luzio Paparatti U, Cozzolino M and On behalf of the FARO-2 Study Group. British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol. 12, Issue. 5
Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study.
Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio Paparatti U, Festa V, Messa P. Int J Nephrol Renovasc Dis. 2014 Dec 16;8:1-6. doi: 10.2147/IJNRD.S72011. eCollection 2015.
Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs.
Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M. Hepat Med. 2015 Jul 13;7:37-42. doi: 2147/HMER.S87594. eCollection 2015.
Chronic Kidney Disease: Evolution Of healthcare Costs And Resource Consumption From Predialysis To Dialysis In Piedmont Region, Italy.
Daniela Paola Roggeri, Alessandro Roggeri and Mario Salomone. Advances In Nephrology, Vol. 2014, article ID 680737, 6 pages, 2014. DOI:10.1155/2014/680737
Gender, socioeconomic position, revascularization procedures and mortality in patients presenting with stemi and nstemi in the era of primary PCI. Differences or inequities?
Roberto Gnavi, Raffaella Rusciani, Marco Dalmasso, Massimo Giammaria, Monica Anselmino, Daniela Paola Roggeri and Alessandro Roggeri. International Journal of Cardiology 176 (2014) 724–730, http://dx.doi.org/10.1016/j.ijcard.2014.07.107
Outcomes, health costs and use of antiplatelet agents in 7082 patients admitted for an Acute Coronary Syndrome occurring in a large community setting.
AP Maggioni, E Rossi, E Cinconze, DP Roggeri, A Roggeri, A Fabbri and M De Rosa, on the behalf of the ARNO Cardiovascular Observatory. Cardiovascular Drugs and Therapy , March 2013 DOI:10.1007/s10557-013-6455-z
Comparison of Fluvastatin + Fenofibrate combination therapy and Fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a twelve month, randomized, double-blind, controlled trial.
G. Derosa, A.F.G. Cicero, G. Bertone, M. Piccinini, L. Ciccarelli, D.P. Roggeri, R. Fogari. Clinical Therapeutics 26:8, 2004. DOI: 10.1016/j.clinthera.2004.10.008
I costi della terapia farmacologia del dolore: farmaci oppioidi e nuovi indicatori di consumo.
D Roggeri; Il Sole 24 Ore Sanità 29/06/2004.
DOLORE
I costi del dolore cronico/ricorrente in medicina generale.
L. Garattini, V. Caimi,S. Cipriani, D. Roggeri, D. Lanzeni, C. Viscarra e Gruppo di Studio PaCo. Pharmacoeconomics Italian Research Articles 5(3): 21-28, 2003
Consumo di risorse e costi per la diagnosi e la cura degli eventi avversi gastrointestinali dovuti all’uso dei Farmaci Anti-infiammatori Non Steroidei (FANS): studio retrospettivo condotto presso i medici di medicina generale.
S. Chiroli, D. Roggeri. Pharmacoeconomics Italian Research Articles 3(2): 61-70,2001.